Could a diabetes drug slow MS brain damage?

NCT ID NCT07497399

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether NLY01, a drug similar to those used for diabetes, can slow brain and retinal shrinkage in people with multiple sclerosis. About 120 adults with stable MS will receive either NLY01 or a placebo for 96 weeks. The main goal is to see if the drug reduces brain tissue loss measured by MRI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NLY01 (a modified version of the diabetes drug exenatide)
What this could lead to: If it works, this could point toward a new way to slow nerve damage and preserve brain tissue in people with multiple sclerosis.
What could go wrong: This is a mid-stage trial with only 120 participants, so results may not apply to everyone. The drug also carries risks like nausea, pancreatitis, and thyroid tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
Mount Sinai School of Medicine
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.